Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing published trials and mechanism-based reasoning without systematic review methodology.
PubMed 30781472 · doi:10.3390/antiox8020044
What was done
This is a narrative review summarizing evidence from randomized controlled clinical trials on the potential role of coenzyme Q10 (CoQ10) supplementation, alone or in combination with selenium, for the prevention and management of degenerative disorders including cardiovascular disease, type II diabetes, chronic kidney disease, and non-alcoholic fatty liver disease.
What was found
The authors note that randomized controlled trials have shown CoQ10 or CoQ10 plus selenium reduces mortality by approximately 50% in patients with cardiovascular disease or in the normal elderly population, respectively. They also report improvements in glycemic control and vascular dysfunction in type II diabetes, improved renal function in chronic kidney disease, and reduced liver inflammation in non-alcoholic fatty liver disease. Specific effect estimates, sample sizes, and confidence intervals for non-mortality outcomes are not reported in the abstract.
Why it matters
The review summarizes how CoQ10 may target shared mechanisms of age-related degenerative conditions through cellular energy generation, antioxidant activity, and anti-inflammatory pathways.
Limits
As a narrative review, it lacks systematic search criteria, risk-of-bias assessment, and meta-analytic synthesis. The abstract does not specify participant numbers, intervention durations, dosages, or adverse effects.
Cited by
- supports Omega-3 fatty acids and coenzyme Q10 (CoQ10) support cardiovascular health, cellular health, and brain health.